The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 01, 2020

Filed:

May. 25, 2016
Applicant:

The Scripps Research Institute, La Jolla, CA (US);

Inventors:

Paul Robbins, Juno Beach, FL (US);

Laura Niedernhofer, Juno Beach, FL (US);

Theodore Kamenecka, Palm Beach Gardens, FL (US);

Gabriela Mustata Wilson, Evansville, IN (US);

Assignee:

THE SCRIPPS RESEARCH INSTITUTE, La Jolla, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 213/74 (2006.01); A61K 31/444 (2006.01); A61K 31/4427 (2006.01); A61K 31/44 (2006.01); A61P 21/00 (2006.01); A61P 9/10 (2006.01); A61P 11/06 (2006.01); A61P 19/02 (2006.01); A61P 3/10 (2006.01); A61P 25/16 (2006.01); A61P 35/00 (2006.01); A61K 31/4439 (2006.01);
U.S. Cl.
CPC ...
A61K 31/444 (2013.01); A61K 31/44 (2013.01); A61K 31/4427 (2013.01); A61K 31/4439 (2013.01); A61P 3/10 (2018.01); A61P 9/10 (2018.01); A61P 11/06 (2018.01); A61P 19/02 (2018.01); A61P 21/00 (2018.01); A61P 25/16 (2018.01); A61P 35/00 (2018.01); C07D 213/74 (2013.01);
Abstract

The invention is directed to a method of inhibiting, within a living cell, the interaction between NF-κB essential modulator ('NEMO') with IκB kinase-β (IKK-β) at the NEMO binding domain (NBD), comprising exposing the cell to an effective amount or concentration of a compound of the invention, a NEMO-binding domain analog (NBDA). The invention is further directed to a method of treating a condition in a patient, wherein inhibiting the interaction between NF-κB essential modulator ('NEMO') with IκB kinase-β (IKK-β) at the NEMO binding domain (NBD) is medically indicated, comprising administering to the patient an effective dose of a compound of the invention. Conditions that can be treated by a method of the invention includes muscular dystrophy, asthma, inflammatory bowel disease, multiple sclerosis, Parkinson's Disease, arthritis, diabetes, graft versus host disease, accelerated aging, heart ischemia, cancer, UV-induced skin damage, or an age-related pathology.


Find Patent Forward Citations

Loading…